Approximately 10--15% of all melanoma patients report a positive family history, multiple primary melanomas or early onset of melanoma diagnosis ([@bib16]). The most important high penetrance gene is the cyclin-dependent kinase Inhibitor 2A (CDKN2A), responsible for about 30% of all familial melanoma cases. Melanoma associated mutations in cyclin-dependent kinase 4 (CDK4), which were also classified as high penetrance mutations, seem to be very rare as only a few families were reported since the initial report in 1996 ([@bib27]). Only recently, a mutation in the telomerase reverse transcriptase gene (TERT) was described in melanoma patients, adding further data to the already existing evidence that stability of telomeres is important in melanoma biology.

Shelterin, a protein complex composed of six subunits, is involved in the protection of the chromosome ends and in the regulation of the telomerase activity ([@bib2]). Recently this complex gained particular interest in melanoma genetics as germline variants were found in 3 shelterin genes in melanoma prone families ([@bib19]; [@bib23]; [@bib2]): POT1, ACD and TERF2IP. The human POT1 gene is located at 7q31.33 and has 19 transcripts. The isoform 1 of the protein, where the variants were originally found, consists of 19 exons and of 634 amino acids. Since the initial description of POT1 as a predisposition gene for hereditary melanoma ([@bib19]; [@bib23]), no further variants associated with melanoma has been described except for one in a single melanoma prone family in the U.S.A. ([@bib26]). Therefore, the frequency of these variants in other populations remains unclear. This information is crucial to decide whether high-risk patients should be tested for POT1 in a routine genetic counseling of melanoma families ([@bib10]). Here we present for the first time data of POT1 variants in high-risk melanoma patients in Austria.

Patients and Methods {#s1}
====================

Study participants {#s2}
------------------

In total, DNA of 694 participants was analyzed. All participants were Caucasians with European ancestry and were recruited in Austria as described elsewhere ([@bib5]). High-risk melanoma patients (n = 296), included patients with multiple primary melanomas (n = 163) and patients with a positive family history (n = 133) and were compared to a reference group of single melanoma (n = 200) and non melanoma patients (n = 198). Descriptive data were shown for gender, age at diagnosis, Breslow index, tumor localization and histological subtype in [Table 1](#t1){ref-type="table"}. In multiple primary melanoma patients, data (date of surgery, localization, histological description such as histological subtype and Breslow index) refers to the first primary melanoma. Informed consent was obtained from all individual participants included in the study. The study was approved by the ethics committee of the Medical University of Vienna.

###### Participant characteristics

                                              Controls      SPM           PFH           \>1 PM
  ------------------------- ----------------- ------------- ------------- ------------- -------------
  Gender                    female            74            80            60            55
                            male              124           120           73            108
  Mean age (SD)                               53.8 (15.8)   52.6 (16.4)   49.7 (15.9)   53.9 (15.1)
                            Missing           0             2             1             0
  Mean Breslow in mm (SD)                     ---           1.4 (1.9)     1.1 (1.3)     1.1 (1.3)
                            Missing/Occult                  10/4          4/3           9/0
  Localization              Head and Neck     ---           15            16            24
                            Upper Extremity   ---           21            12            13
                            Trunk             ---           115           72            85
                            Lower Extremity   ---           43            30            40
                            Missing/Occult    ---           2/4           0/3           1/0
  Histological Subtype      LM/LMM            ---           8             9             19
                            NMM               ---           38            19            25
                            SSM               ---           87            74            74
                            others            ---           67            31            45

SD: standard deviation; LM: lentigo maligna; LMM: lentigo maligna melanoma; NMM: nodular melanoma; SSM: superficial spreading melanoma; SPM: single primary melanoma; PFH: patients with a positive family history; \>1 PM: patients with multiple primary melanomas.

Genotyping {#s3}
----------

The DNA was purified from whole blood as described previously ([@bib5]). Next generation-sequencing of POT1 was performed at the Genome Centre, Queen Mary, University of London (<http://www.smd.qmul.ac.uk/gc/>). For the preparation of DNA libraries 0.5 μg of genomic DNA was used. Amplicon libraries were created with the Fluidigm Access Array according to the manufacturer's protocol. The 150-bp paired-end sequencing was done on the Illumina MiSeq v2 platform.

The datasets generated during the current study are available in the NCBI Sequence Read Archive (<https://www.ncbi.nlm.nih.gov/sra>).

Data analysis {#s4}
-------------

The reads were mapped against human genome reference (hg19) using NextGenMap ([@bib21]) (v0.5.0) with default parameters plus several additional options: identity (-i) was set to 0.85, maximum number of consecutive indels allowed (-C) was set to 120 and we used alignment algorithms that support affine gap costs (--affine). Read groups in aligned reads (BAM files) were replaced using Picard tools (<http://broadinstitute.github.io/picard>) option AddorReplaceReadGroups. The aligned reads were then indexed using SAMtools ([@bib13]) (v1.1). Local realignment around insertions and deletions and quality base score recalibration were performed using the Genome Analysis Tool Kit ([@bib14]) (GATK, v2.6). To call variants (SNPs and indels) in aligned reads files, we used UnifiedGenotyper from GATK with parameters: -dcov set to 2000,--standard_min_confidence_threshold_for_calling set to 30.0, - standard_min_confidence_threshold_for_emitting set to 10, -glm set to BOTH and for option--dbsnp we used human_9606 variants from dbSNP database ([@bib22]). GATK called variants were first divided into SNPs and indels using SelectVariant. SNPs to be filtered out were labeled using VariantFiltration with the following filter expressions:--clusterWindowSize =10, "MQ0 \>= 4 && ((MQ0 / (1.0 \* DP)) \> 0.1)", "DP \< 5", "QUAL \< 30.0 QUAL \> 30.0 && QUAL \< 50.0", "QD \< 0.8", "FS \> 60.0"and

--missingValuesInExpressionsShouldEvaluateAsFailing. Indels to be filtered out were labeled using VariantFiltration with the filter expressions: "QD \< 2.5 \|\| ReadPosRankSum \< -20.0 \|\| FS \> 200.0",

"--missingValuesInExpressionsShouldEvaluateAsFailing". The variants were then combined by GATK CombineVariants tool. Rearranging results was done using our in-house developed python and R scripts.

Prediction analysis of non-synonymous POT1 variants {#s5}
---------------------------------------------------

Two non-synonymous POT1 variants, found in high risk melanoma patients only, were analyzed using 10 prediction tools as described previously ([@bib5]; [@bib16]): MutationTaster2 ([@bib20]), PolyPhen-2 (Polymorphism Phenotyping-v2, HumDiv and HumVar) ([@bib1]), PROVEAN (Protein Variation Effect Analyzer) ([@bib7]), SIFT (sorts intolerant from tolerant substitutions) ([@bib17]), SNAP2 (screening for non-acceptable polymorphisms-2) ([@bib4]), PANTHER (Protein ANalysis THrough Evolutionary Relationships) ([@bib15]), CADD (Combined Annotation Dependent Depletion) ([@bib12]), GERP++ ([@bib9]) and phyloP ([@bib18]). For the latter 2, the tables of the UCSC genome browser tb_allHg19RS_BW and phyloP46wayPlacental were used. Most of those tools provide information about the effect of an amino acid exchange on the protein function. GERP++ and phyloP give a score depending on the conservation by comparing different species. The cut-off score for PROVEAN was -2.5, values below indicate the prediction as deleterious. In SIFT, values have a range from 0 to 1, whereas a score below 0.05 means that the variant is predicted to be deleterious. In CADD values above 15 were classified as deleterious. The range Polyphen2 scores is from values of 0 to 1; higher scores are more likely to be found in deleterious variants with a cut-off score of 0.5. SNAP 2 has output scores between -100 (strong neutral prediction) to 100 (strong effect prediction). PANTHER calculates the preservation time to give a prediction. Longer times indicate a more likely functional impact.

As protein sequence for the data input, the POT1 isoform 1 (ENST00000357628) was used.

Data availability {#s6}
-----------------

All raw sequencing data are deposited in the NCBI Sequence Read Archiv (SRA) under the BioProject ID PRJNA400454.

Results {#s7}
=======

POT1 variants in the entire study population {#s8}
--------------------------------------------

Descriptive data of the study population is shown in [Table 1](#t1){ref-type="table"}. In 694 sequenced individuals, we found 53 genetic variants, 21 of which were not listed in the dbSNP ([@bib22]) (see [Table 2](#t2){ref-type="table"}); 48 were detected in melanoma patients exclusively and 5 additional variants in the control group only. Out of 53 variants, 27 were located in introns, 7 in the 5′ untranslated region (UTR), 10 in the 3′ UTR and 9 in exons (see [Table 2](#t2){ref-type="table"}). Of the latter, 8 resulted in an amino acid exchange and 1 was synonymous. Three non-synonymous variants were located at exon 9, 2 at exon 11 and 1 at exon 7, 14 and 17, respectively. The most common variants in the exons were p.G404V (21 participants), followed by p.D185E (4 participants) and p.V183G (3 participants). All 3 variants were found in cases as well as controls and were listed in the dbSNP ([@bib22]).

###### All variants with localization and their distribution

  Localization   Position    dbSNP         Aminoacid exchange   REF      ALT       Controls   SPM   PFH   \>1 PM
  -------------- ----------- ------------- -------------------- -------- --------- ---------- ----- ----- --------
  5′UTR          124503574   n.a.          ---                  T        C         0          1     0     0
  5′UTR          124537261   rs202009081   ---                  A        G         0          0     1     1
  5′UTR          124568913   n.a.          ---                  C        T         0          0     0     1
  5′UTR          124568914   rs535705635   ---                  G        A         0          2     0     0
  5′UTR          124568963   rs118121031   ---                  T        A         3          1     2     3
  5′UTR          124569916   rs117811540   ---                  G        A         3          3     4     4
  5′UTR          124569930   rs568780254   ---                  C        T         2          1     3     1
  Intron         124465256   rs146966778   ---                  T        C         2          3     3     5
  Intron         124465509   rs10250202    ---                  A        C         131        118   95    110
  Intron         124467236   rs749702835   ---                  T        C         0          0     1     0
  Intron         124469267   rs10263573    ---                  A        T         131        118   95    110
  Intron         124469495   n.a.          ---                  AATT     A         0          1     0     0
  Intron         124475296   rs66826272    ---                  TAAACA   T         74         76    65    75
  Intron         124475296   rs369649621   ---                  T        TAAACA    44         63    0     33
  Intron         124477182   rs7787804     ---                  A        G         179        183   122   149
  Intron         124477188   n.a.          ---                  T        C         1          0     0     0
  Intron         124477270   rs144116156   ---                  A        G         0          2     1     0
  Intron         124481245   rs3815221     ---                  G        A         131        118   94    110
  Intron         124482746   n.a.          ---                  AAATAT   A         0          1     0     0
  Intron         124486898   n.a.          ---                  T        C         1          0     0     0
  Intron         124486928   n.a.          ---                  G        C         1          0     0     1
  Intron         124486968   n.a.          ---                  C        T         1          0     1     0
  Intron         124486980   rs7794637     ---                  T        C         179        183   122   149
  Intron         124486985   n.a.          ---                  CAT      C         1          0     0     0
  Intron         124487064   n.a.          ---                  A        AAAAGGC   0          1     0     0
  Intron         124491886   rs182906205   ---                  T        C         1          0     0     0
  Intron         124492038   rs7784168     ---                  T        C         88         108   63    90
  Intron         124492970   rs751428333   ---                  T        C         0          1     0     0
  Intron         124499002   rs6977407     ---                  A        C         161        176   101   138
  Intron         124499003   rs6959712     ---                  T        A         161        176   101   138
  Intron         124537283   rs112411545   ---                  A        G         2          1     2     0
  Intron         124538285   rs10229152    ---                  G        A         162        176   100   139
  Intron         124538436   rs57468586    ---                  GA       G         168        164   107   121
  Intron         124555710   n.a.          ---                  G        GA        0          1     0     0
  Exon 7         124510982   rs778692211   p.R80C               G        A         0          0     0     1
  Exon 9         124499165   rs200464979   p.V183G              A        C         1          1     1     0
  Exon 9         124499158   rs750899684   p.D185E              A        T         2          0     1     1
  Exon 9         124499092   n.a.          p.L207F              T        A         1          0     0     0
  Exon 11        124491951   rs34398311    p.Q308=              T        C         0          1     0     0
  Exon 11        124491972   rs116916706   p.Q301H              C        A         0          1     0     0
  Exon 11        124491977   n.a.          p.N300H              T        G         0          0     0     1
  Exon 14        124481185   rs35536751    p.G404V              C        A         9          8     3     1
  Exon 17        124467270   n.a.          p.S562P              A        G         0          1     0     0
  3′UTR          124462448   n.a.          ---                  A        C         0          1     0     0
  3′UTR          124462617   rs544668410   ---                  A        C         0          2     0     1
  3′UTR          124462655   rs76436625    ---                  T        C         38         42    28    36
  3′UTR          124462661   rs17246404    ---                  C        T         100        108   53    75
  3′UTR          124463018   rs530211997   ---                  C        T         0          0     0     1
  3′UTR          124463391   n.a.          ---                  CTA      C         159        179   114   135
  3′UTR          124463400   n.a.          ---                  T        C         0          0     0     1
  3′UTR          124463428   rs142378997   ---                  T        G         4          4     5     2
  3′UTR          124463559   n.a.          ---                  T        C         0          0     0     1
  3′UTR          124463612   n.a.          ---                  T        C         0          1     0     0

n.a.: not available; REF: reference sequence; ALT: alteration; SPM: single primary melanoma; PFH: patients with a positive family history; \>1 PM: patients with multiple primary melanomas.

POT1 variants in high-risk patients {#s9}
-----------------------------------

Eight variants were exclusively found in high-risk melanoma patients (see [Table 3](#t3){ref-type="table"}). Four of these 8 variants were not listed in the dbSNP. Of all variants detected in high-risk melanoma patients exclusively (n = 8), 2 were located in the 5′UTR, 3 in the 3′ UTR, 1 in an intron and 2 in exons; 1 in exon 7 and another in exon 11. The latter 2 (g.124510982 G\>A and g.124491977 T\>G) were both found in one multiple primary melanoma patient each. The carrier of g.124510982 G\>A, was a male patient, diagnosed with an amelanotic melanoma at the age of 33 with a second melanoma excised 35 years later and was tested wild type for CDKN2A. The carrier of the other non-synonymous variant, g.124491977 T\>G, was 57 years old when his first primary melanoma was excised. Nine years later, an in-situ melanoma was found on his back.

###### High risk patients and melanoma characteristics

  Variant            dbSNP         Carrier   No. of primaries   1^st^ melanoma               2^nd^ melanoma                 3^rd^ melanoma      4^th^ melanoma   CDKN2A status   Family history of melanoma
  ------------------ ------------- --------- ------------------ ---------------------------- ------------------------------ ------------------- ---------------- --------------- ----------------------------
  g.124537261 A\>G   rs202009081   PFH       1                  49/0.4mm/Lower Extremity     ---                            ---                 ---              wt              Mother 68 years
  g.124537261 A\>G   rs202009081   \>1 PM    4                  47/0.3mm/Shoulder            70/*in situ*/Lower extremity   71/*in situ*/Back   74/2.4mm/Back    wt              negative
  g.124568913 C\>T   n.a.          \>1 PM    2                  66/1mm/Lower extremity       74/5mm/Genital                 ---                 ---              wt              negative
  g.124467236 T\>C   rs749702835   PFH       1                  22/0.4mm/Abdomen             ---                            ---                 ---              c.151-4 G\>GC   Mother 40 years
  g.124510982 G\>A   rs778692211   \>1 PM    2                  33/Unknown/Lower extremity   68/0.45mm/Back                 ---                 ---              wt              negative
  g.124491977 T\>G   n.a.          \>1 PM    2                  57/1mm/Back                  66/*in situ*/Back              ---                 ---              wt              negative
  g.124463018 C\>T   rs530211997   \>1 PM    3                  44/0.75mm/Chest              53/1.6mm/Back                  57/0.4mm/Chest      ---              wt              negative
  g.124463400 T\>C   n.a.          \>1 PM    2                  31/0.5mm/Chest               31/*in situ*/Lower extremity   ---                 ---              wt              negative
  g.124463559 T\>C   n.a.          \>1 PM    2                  36/1mm/Abdomen               53/*in situ*/Lower extremity   ---                 ---              p.R24P          negative

n.a.: not available; PFH: patients with a positive family history; \>1 PM: patients with multiple primary melanomas, wt: wild type.

Of the variants listed in the public SNP databases, g.124467236 T\>C, which was described in a patient with multiple primary melanomas before ([@bib23]), was found in our study in a female patient with a positive family history. She was diagnosed at the age of 22 while her mother had her diagnosis at the age of 40 (which could be confirmed by medical records), conforming with the criteria for inherited risk of melanoma.

The variant g.124537261 A\>G located in the 5′UTR, was the only one found in 2 high-risk patients. Both were diagnosed for melanoma before the age of 50 and tested wild type for CDKN2A mutations. One had a positive family history for melanoma and the other patient was diagnosed with 4 primary melanomas.

Two variants located in the 3′UTR, g.124463018 C\>T and g.124463400 T\>C, were found in early onset patients with multiple primary melanomas each, both tested wild type for CDKN2A mutations.

Prediction analysis of non-synonymous POT1 variants {#s10}
---------------------------------------------------

Prediction analysis was performed for non-synonymous variants in coding sequences which were only found in high-risk melanoma patients: g.124491977 T\>G and g.124510982 G\>A, respectively. While g.124491977 T\>G was predicted to be neutral by all of the used prediction tools, the variant g.124510982 G\>A was predicted to be deleterious by 8 of 10 prediction tools (80%). Results of all prediction analyses are shown in [Table 4](#t4){ref-type="table"}.

###### Prediction of the variant g.124510982 G\>A and g.124491977 T\>G

  Prediction tools   g.124510982 G\>A    g.124491977 T\>G    
  ------------------ ------------------- ------------------- -----------------
  Polyphen2          HumDiv              Probably Damaging   Benign
                     Score               0.987               0.168
                     HumVar              Possibly Damaging   Benign
                     Score               0.791               0.048
  Provean            Prediction          Deleterious         Neutral
                     Score               −5.503              −0.623
  Sift               Effect              Tolerated           Tolerated
                     Score               0.16                0.11
  CADD               PHRED 12 score      31                  0.014
  SNAP2              Prediction          Neutral             Neutral
                     Score               −15                 −89
                     Expected acc.       57%                 93%
  Panther            Preservation time   1628                91
                     Message             Probably damaging   Probably benign
  GERP++             Score               5.57                −4.9
  PhylOP             Score               2.77                −0.470331
  Sum deleterious    Total               8                   0
                     in %                80                  0

Coincidence of CDKN2A mutations {#s11}
-------------------------------

To exclude coincidence with CDKN2A mutations, we then examined the CDKN2A sequence of our cases carrying potential risk variants of POT1. One of the variants found exclusively in high-risk patients, g.124463559 T\>C, was associated with an established CDKN2A high-risk mutation, g.21974756 C\>G (p.R24P). The carrier of the POT1 variant, g.124467236 T\>C, additionally had the CDKN2A variant g. 21971211 G\>C (c.151-4 G\>GC), which was demonstrated to be non-effective in a previous study ([@bib5]).

Discussion {#s12}
==========

Only recently, novel disease associated germline variants in POT1 were reported in melanoma pedigrees ([@bib19]; [@bib23]). This finding is of particular interest as the established disease causing mutations in familial melanoma, *i.e.*, mutations in CDKN2A and CDK4 account only for 30--40% of the melanoma pedigrees. Despite this, just one family with a POT1 germline variant associated with melanoma was published so far ([@bib26]).

In the present study, in which the entire POT1 gene was sequenced in cases at high risk of melanoma and in control patients, a total of 53 variants were found. Despite this, previously published POT1 variants described in melanoma pedigrees ([@bib19]; [@bib23]) were not detected in our study. However, we found the intronic variant, g.124467236 T\>C, in a patient with a positive family history of melanoma which was described in a patient with multiple primary melanomas carrying the variant previously ([@bib23]). The region of the variant g.124467236 T\>C is highly conserved and according to in silico analyses, this variant possibly causes a change in the splice site. Taken together, this finding supports the idea that this variant is associated with melanoma ([@bib23]). Our case with the g.124467236 T\>C germline variant in POT1 harbored a non-effective variant in CDKN2A at the position g. 21971211 G\>C (c.151-4 G\>GC) ([@bib5]). As described previously, no effect on splicing could be confirmed when the transcript was analyzed ([@bib5]).

Of the 53 genetic variants found, 8 were exclusive in high-risk melanoma patients. Two of them, g.124491977 T\>G and g.124510982 G\>A, both non-synonymous variants, were tested for their alleged functionality. While g.124491977 T\>G was predicted to be neutral by all 10 tools, g.124510982 G\>A was predicted to be damaging by 80% of the prediction tools and is therefore very likely to be biologically functional. Comparing the wild type amino acid arginine with the resulting cysteine, there are differences in some amino acid features. The mutant residue is smaller and charged neutral, compared to the negatively charged wild type amino acid. Consequently, the correct folding of the protein could be influenced due to the more hydrophobic nature of the resulting amino acid ([@bib25]).

One potential limitation of this study is the fact that family history was largely reported and histopathologic reports confirming the diagnosis of relatives were not available for all cases. In the current study, the potential effect of the variants was assessed by computational analyses. Naturally, functional analyses are required to determine the exact role of these variants in melanoma development.

In conclusion, melanoma driving POT1 germline variants might be rare. However, further studies are required to assemble comprehensive information on the frequency and the role of POT1 in familial melanoma. It is also important to note that germline variants in POT1 were reported to be associated with other types of cancer such as colorectal cancer ([@bib8]), glioma ([@bib3]) and chronic lymphatic lymphoma ([@bib6]; [@bib11]; [@bib24]). As none of the variants described were found in melanoma cases, further studies might reveal that POT1 variants are specific to specific cancer types.
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